200 related articles for article (PubMed ID: 9690518)
1. Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells.
Carson-Walter EB; Smith DP; Ponder BA; Baylin SB; Nelkin BD
Oncogene; 1998 Jul; 17(3):367-76. PubMed ID: 9690518
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species are critical for the growth and differentiation of medullary thyroid carcinoma cells.
Ha HC; Thiagalingam A; Nelkin BD; Casero RA
Clin Cancer Res; 2000 Sep; 6(9):3783-7. PubMed ID: 10999773
[TBL] [Abstract][Full Text] [Related]
4. Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation.
Carson EB; McMahon M; Baylin SB; Nelkin BD
Cancer Res; 1995 May; 55(10):2048-52. PubMed ID: 7743500
[TBL] [Abstract][Full Text] [Related]
5. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1.
Chen H; Carson-Walter EB; Baylin SB; Nelkin BD; Ball DW
Surgery; 1996 Aug; 120(2):168-72; discussion 173. PubMed ID: 8751579
[TBL] [Abstract][Full Text] [Related]
7. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
[TBL] [Abstract][Full Text] [Related]
9. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.
Park JI; Strock CJ; Ball DW; Nelkin BD
Mol Cell Biol; 2003 Jan; 23(2):543-54. PubMed ID: 12509453
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
Arthan D; Hong SK; Park JI
Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
[TBL] [Abstract][Full Text] [Related]
11. Over-representation of a germline variant in the gene encoding RET co-receptor GFRalpha-1 but not GFRalpha-2 or GFRalpha-3 in cases with sporadic medullary thyroid carcinoma.
Gimm O; Dziema H; Brown J; Hoang-Vu C; Hinze R; Dralle H; Mulligan LM; Eng C
Oncogene; 2001 Apr; 20(17):2161-70. PubMed ID: 11360200
[TBL] [Abstract][Full Text] [Related]
12. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction pathways involving the Raf proto-oncogene.
Williams NG; Roberts TM
Cancer Metastasis Rev; 1994 Mar; 13(1):105-16. PubMed ID: 8143342
[TBL] [Abstract][Full Text] [Related]
14. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant.
Drosten M; Frilling A; Stiewe T; Pützer BM
Surgery; 2002 Dec; 132(6):991-7; discussion 997. PubMed ID: 12490846
[TBL] [Abstract][Full Text] [Related]
15. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells.
Sippel RS; Carpenter JE; Kunnimalaiyaan M; Chen H
Surgery; 2003 Dec; 134(6):866-71; discussion 871-3. PubMed ID: 14668716
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids differentially inhibit expression of the RET proto-oncogene.
Capes-Davis A; Andrew SD; Hyland VJ; Twigg S; Learoyd DL; Dwight T; Marsh DJ; Robinson BG
Gene Expr; 1999; 8(5-6):311-26. PubMed ID: 10947080
[TBL] [Abstract][Full Text] [Related]
17. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
18. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
19. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
Kitamura Y; Goodfellow PJ; Shimizu K; Nagahama M; Ito K; Kitagawa W; Akasu H; Takami H; Tanaka S; Wells SA
Oncogene; 1997 Jun; 14(25):3103-6. PubMed ID: 9223675
[TBL] [Abstract][Full Text] [Related]
20. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.
Santoro M; Rosati R; Grieco M; Berlingieri MT; D'Amato GL; de Franciscis V; Fusco A
Oncogene; 1990 Oct; 5(10):1595-8. PubMed ID: 1701232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
